Exagen Inc.

NASDAQ:XGN

Medical - Diagnostics & Research

Healthcare
$3.90 +3.84%

+$0.16 today

Market cap
$99.50M
Beta
2.02
P/E (TTM)
-5.2
EPS (TTM)
-$0.85
52W Low $2.59High $12.23

Volume 0.47M

Average 0.39M

XGN Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Exagen Inc.NASDAQ: XGN

Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026

Cash & equivalents rises 92.2% from a year ago

Cash & equivalents stood at $21.51M at the end of Q1 FY2026, up 92.2% from a year earlier and down 33.2% from the prior quarter. Over 3 fiscal years it compounded at -19.8% a year.

Context

  • Cash & equivalents amounted to 41.4% of total assets at the end of Q1 FY2026, up 13.6 pp from a year earlier.
  • Cash & equivalents increased in 1 of the last 3 fiscal years.

What to watch

Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +92.2% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$21.51M-33.2% QoQ
Last fiscal yearDec 2025
$32.22M+46.2% YoY
Year agoMar 2025
$11.19M+92.2% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+92.2%——
1 year+46.2%——
3-year CAGR-19.8%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
32.22M USD
Year-over-year change
+46.2%
4-year CAGR
-24.6%

Cash & Equivalents vs competitors

How XGN compares with its peers on the latest reported figures

  • XGN's Mar 2026 cash & equivalents of $21.51M is the 6th highest of the 11 companies compared; the peer median is $23.93M.
  • Its year-over-year change of +92.2% is the highest of 10, against a peer median of -6.1%.
  • Cash & equivalents amounts to 41.4% of total assets for XGN, versus a peer median of 14.5%.
XGN Competitors Peer median
Cash & Equivalents for XGN and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
BIOABioAge Labs, Inc.Mar 2026$241.78M -6.1%+89.8%60.8%
NEONeoGenomics, Inc.Jun 2026$145.54M -5.9%-15.4%10.8%
SGHTSight Sciences, Inc.Mar 2026$84.96M -21.9%-20.8%77.4%
VNDAVanda Pharmaceuticals Inc.Mar 2026$54.03M -51.7%-14.3%12.5%
ACRSAclaris Therapeutics, Inc.Mar 2026$28.66M -5.6%-23.9%14.4%
XGNExagen Inc.Mar 2026$21.51M +92.2%-19.8%41.4%
MDXHMDxHealth S.A.Jun 2026$19.21M -41.5%+23.3%14.5%
LFCRLifecore Biomedical, Inc.Dec 2025$17.47M ——7.5%
STXSStereotaxis, Inc.Mar 2026$14.62M +37.9%+16.1%27.1%
SMTISanara MedTech Inc.Mar 2026$13.59M -34.3%+22.8%19.6%
TKNOAlpha Teknova, Inc.Mar 2026$4.31M +27.5%-48.1%4.4%
Peer median (excluding XGN) $23.93M-6.1%-14.3%14.5%

Competitors are the stored peer set for XGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents99.44M62.39M36.49M22.04M32.22M
Short-term Investments00000
Net Receivables9.65M6.08M6.55M7.84M10.86M
Inventory00000
Other Current Assets490K236K1.93M859K38K
Total Current Assets112.73M72.61M47.84M36.46M48.89M
Property, Plant & Equipment (Net)4.77M13.08M8.49M7.68M8.37M
Goodwill5.51M0000
Intangible Assets00000
Long-term Investments0000200K
Tax Assets00000
Other Non-current Assets433K528K616K550K556K
Total Non-current Assets10.71M13.61M9.1M8.23M9.13M
Total Assets123.45M86.22M56.94M44.69M58.02M
Account Payables2.49M3.05M3.13M4.14M4.15M
Short-term Debt587K190K264K423K3M
Tax Payables00000
Deferred Revenue0000675K
Other Current Liabilities2.19M445K006.33M
Total Current Liabilities9.32M9.62M11.9M13.51M14.16M
Long-term Debt27.48M28.78M19.23M19.82M22.26M
Deferred Tax Liabilities306K0000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities1.41M867K357K157K3.71M
Total Non-current Liabilities29.19M34.14M22.35M21.64M26.41M
Total Liabilities38.51M43.76M34.25M35.15M40.57M
Common Stock16K17K17K18K23K
Retained Earnings(208.14M)(255.53M)(279.22M)(294.33M)(314.28M)
Accumulated OCI00000
Other Stockholders Equity00000
Minority Interest00000
Total Equity84.94M42.46M22.69M9.54M17.45M
Total Debt28.07M35.2M23.23M23.01M25.71M
Net Debt(71.38M)(27.19M)(13.26M)969K(6.51M)

Exagen Inc.

NASDAQ:XGN

Intrinsic Alpha fair value

Locked

Current Price

$3.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.